Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis.
Hofstetter K, Taugner J, Käsmann L, Mansoorian S, Flörsch B, Eze C, Tufman A, Reinmuth N, Duell T, Belka C, Manapov F. Hofstetter K, et al. Among authors: duell t. Strahlenther Onkol. 2023 Nov 17. doi: 10.1007/s00066-023-02175-6. Online ahead of print. Strahlenther Onkol. 2023. PMID: 37975883
 Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study.
Käsmann L, Eze C, Taugner J, Nieto A, Hofstetter K, Kröninger S, Guggenberger J, Kenndoff S, Flörsch B, Tufman A, Reinmuth N, Duell T, Belka C, Manapov F. Käsmann L, et al. Among authors: duell t. J Cancer Res Clin Oncol. 2023 Aug;149(10):7393-7403. doi: 10.1007/s00432-023-04654-w. Epub 2023 Mar 20. J Cancer Res Clin Oncol. 2023. PMID: 36939927 Free PMC article.
Case report: Immunovirotherapy as a novel add-on treatment in a patient with thoracic NUT carcinoma.
Kloker LD, Calukovic B, Benzler K, Golf A, Böhm S, Günther S, Horger M, Haas S, Berchtold S, Beil J, Carter ME, Ganzenmueller T, Singer S, Agaimy A, Stöhr R, Hartmann A, Duell T, Mairhofer S, Fohrer F, Reinmuth N, Zender L, Lauer UM. Kloker LD, et al. Among authors: duell t. Front Oncol. 2022 Oct 27;12:995744. doi: 10.3389/fonc.2022.995744. eCollection 2022. Front Oncol. 2022. PMID: 36387105 Free PMC article.
Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis.
Flörsch B, Taugner J, Käsmann L, Kenndoff S, Guggenberger J, Tufman A, Reinmuth N, Duell T, Belka C, Eze C, Manapov F. Flörsch B, et al. Among authors: duell t. J Cancer Res Clin Oncol. 2023 Jul;149(7):3267-3276. doi: 10.1007/s00432-022-04174-z. Epub 2022 Aug 2. J Cancer Res Clin Oncol. 2023. PMID: 35915184 Free PMC article.
Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
Taugner J, Käsmann L, Karin M, Eze C, Flörsch B, Guggenberger J, Li M, Tufman A, Reinmuth N, Duell T, Belka C, Manapov F. Taugner J, et al. Among authors: duell t. Invest New Drugs. 2022 Feb;40(1):163-171. doi: 10.1007/s10637-021-01143-0. Epub 2021 Aug 5. Invest New Drugs. 2022. PMID: 34351518 Free PMC article. Clinical Trial.
Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial.
Multhoff G, Seier S, Stangl S, Sievert W, Shevtsov M, Werner C, Pockley AG, Blankenstein C, Hildebrandt M, Offner R, Ahrens N, Kokowski K, Hautmann M, Rödel C, Fietkau R, Lubgan D, Huber R, Hautmann H, Duell T, Molls M, Specht H, Haller B, Devecka M, Sauter A, Combs SE. Multhoff G, et al. Among authors: duell t. Clin Cancer Res. 2020 Oct 15;26(20):5368-5379. doi: 10.1158/1078-0432.CCR-20-1141. Epub 2020 Sep 1. Clin Cancer Res. 2020. PMID: 32873573 Clinical Trial.
52 results